Beda Pharmaceuticals: will strive to launch more new drugs in high-incidence tumor areas such as lung cancer and breast cancer.

Beida Pharmaceuticals stated on the interactive platform that the company has gradually achieved the sales of 8 new drugs on the market and has established a promising research and development pipeline with over 20 projects in progress, involving tumors such as lung cancer and breast cancer, as well as eye diseases like wAMD. Currently, the company is focusing its resources on the development of new drugs in high-incidence tumor areas such as lung cancer and breast cancer. In the future, with the implementation of drug promotion strategies, the company's revenue will continue to improve, which will also have a positive impact on its financial indicators.